Association of the antihypertensive response of iptakalim with KCNJ11 (Kir6.2 gene) polymorphisms in Chinese Han hypertensive patients

Acta Pharmacologica Sinica

Volumn 32, Issue 8, 2011, Pages 1078-1084

  Duan, Rui Feng ^a   Cui, Wen Yu ^a   Wang, Hai ^a,b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Thadweik Academy of Medicine   (China)

Author keywords

ATP sensitive potassium channel opener; diastolic blood pressure; genotype; hypertension; iptakalim; KCNJ11; Kir6.2; polymorphisms; systolic blood pressure

Indexed keywords

INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; IPTAKALIM;

3' UNTRANSLATED REGION; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; ESSENTIAL HYPERTENSION; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEX; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

ADULT; AGED; ALLELES; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PROPYLAMINES;

EID: 80051508428     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.85     Document Type: Article

References (30)

1. Zhang S, Mao G, Zhang Y, Tang G, Wen Y, Hong X, et al. Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension. Clin Ther 2005; 27: 1774-84. (Pubitemid 41815228)
2. Taverne K, de Groot M, de Boer A, Klungel O. Genetic polymorphisms related to the renin-angiotensin-aldosterone system and response to antihypertensive drugs. Expert Opin Drug Metab Toxicol 2010; 6: 439-60.
3. Trotta R, Donati MB, Iacoviello L. Trends in pharmacogenomics of drugs acting on hypertension. Pharmacol Res 2004; 49: 351-6. (Pubitemid 38175332)
4. Arnett DK, Claas SA. Pharmacogenetics of antihypertensive treatment: Detailing disciplinary dissonance. Pharmacogenomics 2009; 10: 1295-307.
5. Sherva R, Ford CE, Eckfeldt JH, Davis BR, Boerwinkle E, Arnett DK. Pharmacogenetic effect of the stromelysin (MMP3) polymorphism on stroke risk in relation to antihypertensive treatment: The genetics of hypertension associated treatment study. Stroke 2011; 42: 330-5.
6. Niu Y, Gong Y, Langaee TY, Davis HM, Elewa H, Beitelshees AL, et al. Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the international verapamil srtrandolapril study genetic substudy (INVEST-GENES). Circ Cardiovasc Genet 2010; 3: 548-55.
7. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey K, Cooper- DeHoff RM, et al. Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J 2009; 157: 442-9.
8. Pan Z, Huang J, Cui W, Long C, Zhang Y, Wang H. Targeting hypertension with a new adenosine triphosphate-sensitive potassium channel opener iptakalim. J Cardiovasc Pharmacol 2010; 56: 215-28.
9. Wang H, Zhang YL, Chen YP. Targeting small arteries of hypertensive status with novel ATP-sensitive potassium channel openers. Curr Vasc Pharmacol 2005; 3: 119-24. (Pubitemid 40612985)
10. Gao S, Long CL, Wang RH, Wang H. KATP activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc Res 2009; 83: 444-56.
11. Wang H, Tang Y, Wang L, Long CL, Zhang YL. ATP-sensitive potassium channel openers and 2,3-dimethyl-2-butylamine derivatives. Curr Med Chem 2007; 14: 133-55. (Pubitemid 46043910)
12. Wang H, Long CL, Zhang YL. A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension. J Pharmacol Exp Ther 2005; 312: 1326-33. (Pubitemid 40293797)
13. Chen YP, Qiu CR, Wang H. Cardiovascular pharmacological characterization of novel 2,3-dimethyl-2-butylamine derivatives in rats. Life Sci 2004; 75: 2131-42. (Pubitemid 39092997)
14. Chen YP, Cui WY, Wang H. Selective actions of iptakalim on the subtypes of KATP channels. Chin Pharmacol Bull 2006; 22: 278-84. (Pubitemid 43953476)
15. Long CL, Qin XC, Pan ZY, Chen K, Zhang YF, Cui WY, et al. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia. J Hypertens 2008; 26: 2326-38.
16. Duan RF, Cui WY, Gao HY, Wang XP, Hu SK, Liu W, et al. Correlation between ACE gene I/D polymorphism and clinical efficacy of iptakalim in Chinese Han hypertensive population. Chin J Clin Pharmacol Ther2010; 15: 961-6.
17. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286: 487-91.
18. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15: 97-8. (Pubitemid 41653949)
19. Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, et al. A partition- ligationcombination- subdivision EM algorithm for haplotype inference with multiallelic markers: Update of the SHEsis (http://analysis.bio-x.cn). Cell Res 2009; 19: 519-23.
20. Nichols CG. KATP channels as molecular sensors of cellular metabolism. Nature 2006; 440: 470-6.
21. Jeron A, Hengstenberg C, Holmer S, Wollnik B, Riegger GA, Schunkert H, et al. KCNJ11 polymorphisms and sudden cardiac death in patients with acute myocardial infarction. J Mol Cell Cardiol 2004; 36: 287-293. (Pubitemid 38202357)
22. Riedel MJ, Boora P, Steckley D, de Vries G, Light PE. Kir6.2 polymorphisms sensitize beta-cell ATP-sensitive potassium channels to activation by acyl CoAs: A possible cellular mechanism for increased susceptibility to type 2 diabetes? Diabetes 2003; 52: 2630-5. (Pubitemid 37210554)
23. Xiong C, Zheng F, Wan J, Zhou X, Yin Z, Sun X. The E23K polymorphism in Kir6.2 gene and coronary heart disease. Clin Chim Acta 2006; 367: 93-7.
24. Reyes S, Terzic A, Mahoney DW, Redfield MM, Rodeheffer RJ, Olson TM. KATP channel polymorphism is associated with left ventricular size in hypertensive individuals: A large-scale community-based study. Hum Genet 2008; 123: 665-7.
25. Suzuki M, Li RA, Miki T, Uemura H, Sakamoto N, Ohmoto-Sekine Y, et al. Functional roles of cardiac and vascular ATP-sensitive potassium channels clarified by Kir6.2-knockout mice. Circ Res 2001; 88: 570-7. (Pubitemid 32275792)
26. He YY, Zhang R, Shao XY, Hu C, Wang CR, Lu JX, et al. Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. Acta Pharmacol Sin 2008; 29: 983-9.
27. Yu M, Xu XJ, Yin JY, Wu J, Chen X, Gong ZC, et al. KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. Clin Pharmacol Ther 2010; 87: 330-5.
28. Koo BK, Cho YM, Park BL, Cheong HS, Shin HD, Jang HC, et al. Polymorphisms of KCNJ11 (Kir6.2 gene) are associated with Type 2 diabetes and hypertension in the Korean population. Diabet Med 2007; 24: 178-86. (Pubitemid 46174942)
29. Kokubo Y, Tomoike H, Tanaka C, Banno M, Okuda T, Inamoto N, et al. Association of sixty-one non-synonymous polymorphisms in fortyone hypertension candidate genes with blood pressure variation and hypertension. Hypertens Res 2006; 29: 611-9. (Pubitemid 44430470)
30. Sakamoto Y, Inoue H, Keshavarz P, Miyawaki K, Yamaguchi Y, Moritani M, et al. SNPs in the KCNJ11-ABCC8 gene locus are associated with type 2 diabetes and blood pressure levels in the Japanese population. J Hum Gene 2007; 52: 781-93. (Pubitemid 47512860)